



July 29, 2020

To

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India

Dear Sirs,

Subject : Intimation regarding receipt of disclosure received from the acquirer in terms of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Stock Code: BSE - 539787, NSE – HCG

Reference: Regulation 29 (1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29 (1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 we submit herewith copy of disclosure received from Aceso Company Pte. Ltd (“the Acquirer”), with respect to acquisition of (i) 29,516,260 equity shares and 18,560,663 warrants; and (ii) 7,057,195 equity shares on conversion of 7,057,195 warrants out of the total 18,560,663 warrants (i.e. 36,573,455 equity shares and 11,503,468 warrants post conversion of 7,057,195 warrants) of HealthCare Global Enterprises Limited.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Enclosure: as above

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489

Aceso Company Pte. Ltd. (UEN. 202010289R)
38 Beach Road #29-11 South Beach Tower Singapore 189767

July 29, 2020

National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India E-mail: takeover@nse.co.in Stock Code: NSE – HCG	BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India E-mail: corp.relations@bseindia.com Stock Code: BSE – 539787	HealthCare Global Enterprises Limited, Compliance Officer, #8, 'HCG Towers', P. Kalinga Rao Road Sampangi Ram Nagar, Bangalore - 560 027, India E-mail: sunumanuel@hcgel.com
---	---	--

Dear Sir/Madam,

Subject : Disclosure under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of acquisition of equity shares and warrants of HealthCare Global Enterprises Limited.

This is to inform you that ACESO COMPANY PTE. LTD has acquired (i) 29,516,260 equity shares and 18,560,663 warrants; and (ii) 7,057,195 equity shares on conversion of 7,057,195 warrants out of the total 18,560,663 warrants (i.e. 36,573,455 equity shares and 11,503,468 warrants post conversion of 7,057,195 warrants).

In view of the above, please find attached the requisite disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **ACESO COMPANY PTE. LTD**



Name: Tan Ting Luen

Designation: Director

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Part A – Details of the Acquisition

Name of the Target Company (TC)	HealthCare Global Enterprises Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<ol style="list-style-type: none"> 1. Acquirer – Aceso Company Pte. Ltd. (Acquirer); 2. PAC 1 – Aceso Investment Holdings Pte. Ltd.; 3. PAC 2 – CVC Capital Partners Asia V L.P.; 4. PAC 3 – CVC Capital Partners Investment Asia V L.P.; and 5. PAC 4 – CVC Capital Partners Asia V Associates L.P. 		
Whether the Acquirer belongs to Promoter/ Promoter group	Pursuant to the acquisition, the Acquirer shall be classified as a Promoter.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited BSE Limited		
Details of the acquisition as follows	<i>Number</i>	<i>% w.r.t. total share/voting capital wherever applicable(*)</i>	<i>% w.r.t. total diluted share/voting capital of the TC (**)</i>
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	-	-	-
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	-	-	-

Aceso Company Pte. Ltd. (UEN. 202010289R)
38 Beach Road #29-11 South Beach Tower Singapore 189767

Details of acquisition			
a) Shares carrying voting rights acquired	36,573,455 Equity Shares of face value INR 10	29.20 %	26.36%
b) VRs acquired otherwise than by equity shares.	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	11,503,468 Warrants convertible into Equal number of Equity Shares.	-	8.29%
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	48,076,923	29.20%	34.65%
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	36,573,455 Equity Shares of face value INR 10	29.20 %	26.36%
b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	11,503,468 Warrants convertible into Equal number of Equity Shares.	-	8.29%

Aceso Company Pte. Ltd. (UEN. 202010289R)
38 Beach Road #29-11 South Beach Tower Singapore 189767

d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+d)	48,076,923	29.20%	34.65%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	<p>Preferential Allotment of 29,516,260 equity shares and 18,560,663 warrants representing the right to subscribe to 18,560,663 equity shares of the Target Company.</p> <p>Out of the 18,560,663 warrants, 7,057,195 warrants were exercised pursuant to Investment Agreement and 7,057,195 equity shares were issued on exercise of warrants on 28 July 2020. Thereby an aggregate of 36,573,455 equity shares and 11,503,468 warrants (post conversion of 7,057,195 warrants) were acquired.</p>		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	18,560,663 warrants representing the right to subscribe to 18,560,663 equity shares of the Target Company at premium of Rs. 120 per equity share.		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	28 July 2020		
Equity share capital / total voting capital of the TC before the said acquisition	8,86,90,629 equity shares having a face value of INR 10 each		
Equity share capital/ total voting capital of the TC after the said acquisition	12,52,64,084 equity shares having a face value of INR 10 each		
Total diluted share/voting capital of the TC after the said acquisition	13,87,67,552 equity shares having a face value of INR 10 each (assuming full conversion of 11,503,468 Series A warrants and 20,00,000 Series B warrants)		

Signature of the acquirer / Authorised Signatory

ACESO COMPANY PTE. LTD

A handwritten signature in black ink, consisting of stylized initials and a long horizontal stroke extending to the right.

Place: Singapore

Date: 29 July 2020

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the Company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.